F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective
Fabrice Barlesi,Cécile Tchouhadjian,Christophe Doddoli,Patrick Villani,L. Greillier,Jean-Pierre Kleisbauer,Pascal Thomas,Philippe Astoul +7 more
TL;DR: The efficacy of gefitinib in the first‐line setting of each stage of NSCLC has to be further studied through clinical trials and translational studies characterizing the molecular features involved in the response to anti‐EGFR‐targeted therapies are needed.
Journal ArticleDOI
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Roy S. Herbst,Margarita Majem,Fabrice Barlesi,Enric Carcereny,Quincy Chu,Isabelle Monnet,A Sanchez-Hernandez,Shaker R. Dakhil,D. Ross Camidge,Leanne Winzer,Yee Soo-Hoo,Zachary A. Cooper,Rajesh Kumar,John Bothos,Charu C. Aggarwal,Alex Martinez-Marti +15 more
TL;DR: Both combinations increased ORR and prolonged PFS versus durvalumab alone and safety was similar across arms with no new or significant safety signals identified with either combination, which support their further evaluation in a phase III trial.
Journal ArticleDOI
EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
Pascale Tomasini,Cindy Serdjebi,N. Khobta,Philippe Metellus,L'Houcine Ouafik,Isabelle Nanni,Laurent Greillier,Anderson Loundou,Frédéric Fina,C. Mascaux,Fabrice Barlesi +10 more
TL;DR: EGFR and KRAS mutations have a predictive role on BM incidence, recurrence and outcome in Caucasian NSCLC patients and may impact the routine management of disease in these patients.
Journal ArticleDOI
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Suresh S. Ramalingam,Jeffrey Crawford,A. Chang,Christian Manegold,Roman Perez-Soler,J.-Y. Douillard,Nick Thatcher,Fabrice Barlesi,Taofeek K. Owonikoko,Y. Wang,P. Pultar,J. Zhu,R. Malik,Giuseppe Giaccone,Stephen Della-Fiorentina,Stephen Begbie,Ross Jennens,J. Dass,K. Pittman,N. Ivanova,T. Koynova,Petar Petrov,A. Tomova,V. Tzekova,Félix Couture,V. Hirsh,R. Burkes,R. Sangha,M. Ambrus,T. Janaskova,J. Musil,J. Novotny,P. Zatloukal,J. Jakesova,K. Klenha,J. Roubec,J. Vanasek,J. Fayette,J. Bennouna-Louridi,Christos Chouaid,Julien Mazieres,H. Vallerand,Gilles Robinet,Pierre-Jean Souquet,D. Spaeth,Roland Schott,Hervé Lena,Y. Martinet,C. El Kouri,N. Baize,Arnaud Scherpereel,Olivier Molinier,F. Fuchs,K. M. Josten,Norbert Marschner,Folker Schneller,T. Overbeck,Michael Thomas,J. von Pawel,Martin Reck,Wolfgang Schuette,V. Hagen,Claus-Peter Schneider,Vassilis Georgoulias,I. Varthalitis,K. Zarogoulidis,Kostas N. Syrigos,Christos Papandreou,C. Bocskei,Eszter Csánky,E. Juhasz,György Losonczy,Z. Mark,I. Molnar,Z. Papai-Szekely,S. Tehenes,I. Vinkler,S. Almel,A. Bakshi,S. Bondarde,A. Maru,A. Pathak,R. M. Pedapenki,K. Prasad,S. V S S Prasad,N. Kilara,D. Gorijavolu,C. D. Deshmukh,Shinu John,L. M. Sharma,Domenico Amoroso,Emilio Bajetta,P. Bidoli,Andrea Bonetti,F. De Marinis,Michele Maio,Rodolfo Passalacqua,Stefano Cascinu,Alessandra Bearz,M. Bitina,A. Brize,G. Purkalne,M. Skrodele,A. A. Baba,K. Ratnavelu,M. H. Saw,M. C. Samson-Fernando,G. E. Ladrera,Jacek Jassem,P. Koralewski,Piotr Serwatowski,Maciej Krzakowski,C. Cebotaru,D. Filip,D. E. Ganea-Motan,C. H. Ianuli,I. G. Manolescu,A. Udrea,O. Burdaeva,M. Byakhov,A. Filippov,S. Lazarev,I. Mosin,Sergey Orlov,D. Udovitsa,A. Khorinko,S. Protsenko,H. L. Lim,Y. O. Tan,E. H. Tan,R. Bastus Piulats,J. Garcia-Foncillas,Javier Valdivia,J. de Castro,M. Domine Gomez,S. W. Kim,J. S. Lee,H. K. Kim,S. W. Shin,D. W. Kim,Y. C. Kim,K. C. Park,C. S. Chang,G. C. Chang,Y. G. Goan,W. C. Su,C. M. Tsai,H. P. Kuo,Mustafa Benekli,Gokhan Demir,Erhan Gokmen,Alper Sevinc,Missak Haigentz,Manyoo Agarwal,S. Pandit,R. Araujo,N. Vrindavanam,Philip Bonomi,A. Berg,James L. Wade,R. Bloom,B. Amin,R. Camidge,D. Hill,M. Rarick,Patrick J. Flynn,L. Klein,K. Lo Russo,M. Neubauer,P. Richards,R. Ruxer,M. Savin,D. Weckstein,R. Rosenberg,T. Whittaker,Donald A. Richards,William R. Berry,Christian H. Ottensmeier,Adam Dangoor,Nicola Steele,Yvonne Summers,E. Rankin,K. Rowley,S. Giridharan,H. Kristeleit,C. Humber,Paul D. Taylor +186 more
TL;DR: There was no improvement in efficacy with talactoferrin alfa in patients with advanced NSCLC whose disease had failed two or more prior regimens and the safety profiles were comparable between arms.
Journal ArticleDOI
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
Fabrice Barlesi,Edward B. Garon,Dong Wan Kim,Enriqueta Felip,Ji Youn Han,Joo Hang Kim,Myung-Ju Ahn,Mary J. Fidler,Matthew A. Gubens,Gilberto de Castro,Veerle Surmont,Qiao Li,Anne C. Deitz,Gregory M. Lubiniecki,Roy S. Herbst +14 more
TL;DR: It is suggested that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.